Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1995-07-11
2000-11-14
Stucker, Jeffrey
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
4241421, 4241431, 4241471, 4241481, 4241831, 4241841, 4241871, A61K 39395, A61K 3940, A61K 3942, A61K 3944
Patent
active
06146628&
ABSTRACT:
Biotherapeutic agents are provided which comprise recombinant PAP or a biologically equivalent variant or mutant thereof, linked to a targeting moiety which are effective for the treatment of certain human diseases. The invention further provides a process for producing the biotherapeutic agents as well as a method which utilizes the disclosed biotherapeutic agents to systemically treat cancer patients.
REFERENCES:
patent: 4340535 (1982-07-01), Voisin et al.
patent: 4363758 (1982-12-01), Masuho et al.
patent: 4671958 (1987-06-01), Rodwell
patent: 4831117 (1989-05-01), Uckun
patent: 5167956 (1992-12-01), Neville, Jr. et al.
patent: 5304730 (1994-04-01), Lawson et al.
patent: 5690935 (1997-11-01), Uckun et al.
Abel et al., Science 232: 738-43 (1986).
Aron et al., Antimicrob. Agents Chemotherapy, 17, 1032 (1980).
Bolognesi, et al., Clin. Exp. Immunol. 89:341 (1992).
Bruland, et al., Int. J. Cancer 38:27 (1986).
Bruland, Cancer Res 48:5302 (1988).
Bruland and Pihl, In: Frontiers of Osteosarcoma Research (1993).
Byers, et al., AIDS, 4, 1189 (1990).
Cannistern, et al., J.B. Chem. 265:12656(1990).
Chelstrom et al., Blood, 84, 20 (1994).
Endo et al., Biophys. Res. Comm., 150:1032-36 (1988).
Erice et al., Antimicrob. Ag. Chemother., 37, 835 (1993).
Erice et al., J. Clin. Microbiol., 30, 444 (1992).
Golemboski et al., Proc. Natl. Acad. Sci. USA 87:6311-15 (1990).
Gould et al., J. Natl. Cancer Inst., 81, 775 (1989).
Gunther, et al., Blood 85:2537-2545 (May 1995).
Hartley et al., FEBS Lett. 290:65-68 (1991).
Hayashi et al., J. Bioenerg. Biomem. 22:451-71 (1990).
Hemenway et al., EMBO J. 7:1273-80 (1988).
Higashigawa, et al., Leukemia Research 16:1049(1992).
Houston, et al., In: Immunological Antibody Conjugates in Radioimaging and Therapy of Cancer, Vogel ed. NY, Oxford Univ. Press, p. 71 (1987).
Hoxie et al., Science, 234, 1123 (1986).
Irvin, et al., Pharmacol. and Therapeutics 55:279(1992).
Ito et al., J. Bacteriol., 153, 163 (1983).
Jackson et al., J. Clin. Microbiol., 28, 16 (1990).
Lee, et al., Nature 289:407(1981).
Lee-Huang et al., FEBS Lett., 272, 12 (1990).
Linsley et al., J. Virol., 62, 3695 (1988).
Lodge et al., Proc. Natl. Acad. Sci. USA 90:7089-93 (1993).
Meyers et al., Journal of Immunological Methods, 136, 221 (1991).
Monzingo et al., J. Molecular Biol., 233, 705 (1993).
Mosier et al., Science, 251, 791 (1991).
Myers, et al., J. Immunol. Methods 136:221-238(1991).
Olson et al., AIDS Res. Human Retroviruses, 7, 1025 (1991).
Pastan, et al., Science, 254:1173(1991).
Saksela et al., Proc. Natl. Acad. Sci. U.S.A., 91, 1104 (1994).
Schnittman et al., Science, 245, 305 (1989).
Soler-Rodriguez et al., Experimental Cell Research, 206, 227 (1993).
Stevens et al., Experientia, 37, 257 (1981).
Teltow et al., Antimicrob. Ag. Chemother., 23, 390 (1983).
Thorpe, Cancer Res. 47:5924(1987).
Uckun, et al., In: Human Tumor Antigens and Specific Tumor Therapy, UCLA Symposium Molecular Cellular Biology, New Ser (1989) pp. 231-241.
Uckun, et al., J. Exp. Med. 163:347(1986).
Uckun, et al., Proc. Natl. Acad. Sci. U.S.A., 85, 8603 (1988).
Uckun, et al., Blood 71:13 (1988).
Uckun, et al., Blood, 76, 1723 (1990).
Uckun, et al., Blood, 76, 1908 (1990).
Uckun, et al., Third Int'l. Symposium on Immunotoxins, p. 131(1992).
Uckun, et al., Blood 79:2201(May 1992).
Uckun, et al., Blood 79:3116 (Jun. 1992).
Uckun, et al., Blood 79:3369 (Jun. 1992).
Uckun, et al., Br. J. Haemotol 85:435(1993).
Uckun, et al., Leukemia 7:341 (1993).
Uckun, et al., Leukemia and Lymphoma 9:459-476 (Apr. 1993).
Ussery et al., Ann, N. Y. Acad. Sci, 284, 431 (1977).
Van Leeuwen, et al., Blood 73:1142(1989).
Yang, et al., Cell 47:3(1986).
Zarling et al. Nature, 347, 92 (1990).
Uckun, et al. : A clinical phase I dose escalation . . .: Program and Abstracts Third Intern. Symp. on Immuno.: p. 131, Jun. 1992.
Jain, et al. : Barriers to drug delivery in solid tumors: Sci. Am. : 271(1): pp. 58-65, Jul. 1994.
Osband et al. : Problems in the investigational study and . . .: Immunol. Tod. : 11(6): pp. 193-195, 1990.
Myers, et al. : Production of a pokeweed antiviral protein . . .: J. Immun. Meth.: 136: pp. 221-238, 1991.
Zarling, et al. : Inhibition of HIV replication by pokeweed . . .: Nature: v. 347: pp. 92-95, Sep. 1990.
Burgess, et al. : Possible dissociation of the heparin-binding . . .: J. Cell Bio.: vol. 111: pp. 2129-2138, 1990.
Lazar, et al. : Transforming growth factor . . .: Mol. Cell. Bio. : vol. 8, No. 3: pp. 1247-1252, Mar. 1988.
Tao, et al. : Studies of aglycosylated chimeric . . .: J. Immun. : vol. 143, No. 8: pp. 2595-2601, Oct. 1989.
Tumer Nilgun E.
Uckun Fatih M.
Nelson Brett
Regents of the University of Minnesota and Rutgers
Stucker Jeffrey
The State University of New Jersey
LandOfFree
Biotherapeutic agents comprising recombinant PAP and PAP mutants does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biotherapeutic agents comprising recombinant PAP and PAP mutants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biotherapeutic agents comprising recombinant PAP and PAP mutants will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2062304